The funds will be used to increase the development of GAIA-based Alzheimer's disease drugs and widen the pipeline of blockbuster drug candidates.

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug. They ...

Bristol-Myers Squibb’s trading volume rocketed to 6.93 billion on July 15, securing the 138th spot in market rankings. The company unveiled a strategic partnership with a biotech firm to develop ...

Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

The Food and Drug Administration (FDA) has updated the labeling for Kisunla ™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...